Hall K S, Lien B, Paulsen J E, Clausen O P, Bergan A, Rugstad H E
Department of Clinical Pharmacology, Rikshospitalet, Oslo, Norway.
Eur Surg Res. 1989;21(3-4):196-204. doi: 10.1159/000129024.
The early effects of 4'-epidoxorubicin (Epi-Adriamycin) on liver regeneration and late effects on liver function were studied after a standard partial hepatectomy in rats. 4'-epidoxorubicin was given intravenously immediately preoperatively. Neither suppression nor delay in DNA synthesis (analyzed by incorporation of 3H-thymidine) during the first 72 h postoperatively was registered after a dose of 5 mg/kg body weight. Four weeks following the dose of 5 mg/kg a slight decrease was found in liver weight (8%), body weight (8%) and plasma albumin values (9%) compared with the partial hepatectomized controls. Total protein, alkaline phosphatase, total bilirubin and alanine aminotransferase were not changed. A dose of 2 mg/kg did not alter any of the parameters. No histological signs of liver and kidney damage were seen. The results indicate that preoperative treatment with 4'-epidoxorubicin combined with partial hepatectomy may possibly be used in humans without clinically significant impairment of liver regeneration and function of the remaining liver and without histological detectable nephrotoxicity. The dosage of 4'-epidoxorubicin must, however, be adjusted according to species differences in pharmacokinetics.
在大鼠进行标准部分肝切除术后,研究了4'-表阿霉素(表阿霉素)对肝脏再生的早期影响以及对肝功能的晚期影响。术前立即静脉注射4'-表阿霉素。给予5mg/kg体重的剂量后,术后72小时内未观察到DNA合成(通过掺入3H-胸腺嘧啶分析)受到抑制或延迟。给予5mg/kg剂量四周后,与部分肝切除的对照组相比,肝脏重量(8%)、体重(8%)和血浆白蛋白值(9%)略有下降。总蛋白、碱性磷酸酶、总胆红素和丙氨酸转氨酶未发生变化。2mg/kg的剂量未改变任何参数。未观察到肝脏和肾脏损伤的组织学迹象。结果表明,术前用4'-表阿霉素联合部分肝切除术治疗可能可用于人类,而不会对肝脏再生和剩余肝脏功能造成临床上显著的损害,也不会出现组织学可检测到的肾毒性。然而,4'-表阿霉素的剂量必须根据药代动力学的物种差异进行调整。